The efficacy and safety of a therapy regimen including raltegravir and a fixed dose combination of lamivudine and abacavir in previously rifabutin-treated patients with tuberculosis and HIV infection

AIM. To evaluate the efficiency and safety of using raltegravir (RAL) twice daily in conjunction with a once-daily fixed dose combination of abacavir (ABC)/lamivudine (3TC) in patients with HIV infection and active tuberculosis who have not previously received antiretroviral therapy (ART) and have t...

Full description

Bibliographic Details
Main Authors: A V Kravchenko, V N Zimina, A A Popova, M O Deulina, V G Kanestri, É S Ivanova, A A Iakovlev, V V Pokrovskiĭ
Format: Article
Language:Russian
Published: "Consilium Medicum" Publishing house 2014-11-01
Series:Терапевтический архив
Subjects:
Online Access:https://ter-arkhiv.ru/0040-3660/article/view/31650